Search | Clinical Trials Finder

Conditions: Anal Cancer
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions: SOMA pain manager smartphone application; Device
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Gastroparesis
Interventions: MRI scan; Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Lung Disease
Interventions: Infant Pulmonary Function Tests; Procedure
Lead sponsor: University of Tennessee; Other
Eligibility: 1 Month to 24 Months
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 33
States / cities: Tucson, Arizona • Long Beach, California • Palo Alto, California + 28 more

Conditions: Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions: DNK333, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 180 participants
Timeline: 2006 – 2007
U.S. locations: 37
States / cities: Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more

Conditions: Irritable Bowel Syndrome, Functional Abdominal Pain Syndrome, Functional Gastrointestinal Disorders, Functional Bowel Disorder, Functional Abdominal Pain, Functional Abdominal Pain Disorders
Interventions: Cognitive Behavioral Therapy, Low FODMAP Diet; Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 7 Years to 12 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Irritable Bowel Syndrome With Diarrhea
Interventions: CIN-103, Placebo; Drug
Lead sponsor: CinPhloro Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more

Conditions: Esophageal Diseases
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Temple University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Irritable Bowel Syndrome (IBS)
Interventions: ONO-2952, Placebo comparator; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 4
States / cities: Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more

Conditions: Hepatic Impairment
Interventions: ABT-493, ABT-530; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Liver Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
Interventions: Hepatobiliary Iminodiacetic Acid (HIDA) scan; Diagnostic Test
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Gastric Neoplasms, Pancreatic Neoplasms, Small Intestinal Neoplasms, Colorectal Neoplasms
Interventions: BRAHMS CgA II KRYPTOR; Diagnostic Test
Lead sponsor: Brahms AG; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Palo Alto, California • Rochester, Minnesota • Houston, Texas

Conditions: Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Celiac Disease, Diarrhea, Constipation, Microbiome, Crohn's Disease, UC - Ulcerative Colitis, Microscopic Colitis, Functional Dyspepsia
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-Alcoholic Fatty Liver Disease
Interventions: Weight loss surgery; Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Irritable Bowel Syndrome With Constipation
Interventions: Linaclotide Acetate, Matching placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 79
States / cities: Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more

Conditions: Gastroparesis
Interventions: EndoFLIP, Antroduodenal Manometry; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Scoliosis
Interventions: Chewing gum, Control; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 10 Years to 18 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Bladder Cancer, Ileus, Narcotic Use
Interventions: Use of a pedometer following surgery, Standard of care; Behavioral
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Crohn's Disease
Interventions: GED-0301, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 12 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: San Diego, California • Atlanta, Georgia • Indianapolis, Indiana + 18 more

Conditions: Diabetes, Insulin Resistance, Obesity, Bariatric Surgery Candidate, Roux-en-y Gastric Bypass, Liver Diseases
Interventions: Endoscopy biopsy, Surgical biopsy, Mixed-meal tolerance test, Excised Liver Tissue Sampling; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Irritable Bowel Syndrome
Interventions: Placebo, Camlipixant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 108
States / cities: Anniston, Alabama • Guntersville, Alabama • Mobile, Alabama + 88 more

Conditions: Irritable Bowel Syndrome
Interventions: Rifaximin; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 67
States / cities: Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 61 more

Conditions: Liver Diseases
Interventions: Etavopivat; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 5
States / cities: Orange, California • Orlando, Florida • San Antonio, Texas

Search by objective public record fields.

QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

Magnetic Resonance Imaging of the Brain and Stomach in Healthy Volunteers and Gastroparesis

A Pilot Study of Pulmonary Function in Dysphagic Infants

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function

A Pilot Study to Assess Theragnostically Planned Liver Radiation to Optimize Radiation Therapy

Chromogranin A as Blood Marker in Cancer Patients

Enabling Microbiomics- Driven Personalized Nutrition

Liver Health and Metabolic Function in People With Obesity

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Use of EndoFLIP and Manometry Prior to G-POEM

Chewing Gum Facilitates an Earlier Return to Bowel Function in Pediatric Scoliosis Patients: A Prospective Randomized Study

Use of Pedometer Following Radical Cystectomy

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

Physiologic and Functional Adaptations of Insulin Sensitive Tissues

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

A Research Study on Etavopivat in Participants With and Without Liver Disease